Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial
Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial
About this item
Full title
Author / Creator
Nieves, J.W. , Cosman, F. , McMahon, D. , Redko, M. , Hentschel, I. , Bartolotta, R. , Loftus, M. , Kazam, J.J. , Rotman, J. and Lane, J.
Publisher
London: Springer London
Journal title
Language
English
Formats
Publication information
Publisher
London: Springer London
Subjects
More information
Scope and Contents
Contents
Summary
Pelvic fracture patients were randomized to blinded daily subcutaneous teriparatide (TPTD) or placebo to assess healing and functional outcomes over 3 months. With TPTD, there was no evidence of improved healing by CT or pain reduction; however, physical performance improved with TPTD but not placebo (group difference
p
< 0.03).
Alternative Titles
Full title
Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8758515
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8758515
Other Identifiers
ISSN
0937-941X
E-ISSN
1433-2965
DOI
10.1007/s00198-021-06065-4
